Articles tagged with Sars Cov 2
A study published in PLOS ONE found that people in Europe primarily consume trustworthy news, but a small percentage rely on questionable sources. The ratio of questionable news to reliable news consumption differs between countries, highlighting the need for context-specific approaches to fighting misinformation.
Researchers developed a new 'proactive vaccinology' approach to build vaccines before disease-causing pathogens emerge. The Quartet Nanocage vaccine trains the immune system to target specific regions of eight coronaviruses, providing broad protection against known and unknown strains.
Researchers found that SARS-CoV-2 spike protein interrupts p53-MDM2 interaction but does not bind with p53 protein in cancer cells. The study also shows that SARS-CoV-2 spike suppresses p53-dependent gene activation, leading to increased cell viability after chemotherapy exposure.
A team of scientists has developed a novel vaccine approach that induces long-lasting protective immunity against SARS-CoV-2 virus in pre-clinical models. The Clec9A-RBD antibody construct targets specific dendritic cells, leading to exceptional durability of immune responses and potential to address shortcoming of current mRNA vaccines.
Researchers found that T cells and memory B cells provide durable protection against symptomatic SARS-CoV-2 infection, with levels attainable after two doses of mRNA vaccination. The study suggests a two-dose vaccination regimen for children against COVID-19.
A new survey of 23,000 respondents from 23 countries reports mixed signals on the current acceptance of vaccines generally, especially COVID-19 boosters. The study found that global uptake of at least one COVID-19 vaccine dose rose to 87.8%, but intent to get a booster was lower compared to previous years.
A systematic review and meta-analysis found no association between new-onset seizures and SARS-CoV-2 vaccination. The study included over 118,000 participants from randomized clinical trials and found the incidence proportion of new-onset seizures to be similar across vaccine recipients and unvaccinated participants.
Researchers found that increased CO2 concentrations prolong the life of SARS-CoV-2 variants in airborne particles, increasing transmission risk. Fresh air with lower CO2 levels can inactivate viruses faster, making opening windows an effective mitigation strategy.
Researchers at University of Kansas discover a new compound that inhibits SARS-CoV-2 replication in cell models by targeting the 'Mac-1' protein. This finding offers hope for developing new treatments and preventing future pandemics.
A large-scale study of 3.9 million children found that COVID-19 vaccination significantly reduced the incidence of SARS-CoV-2 infection and hospitalization among kids in California. The study suggests that vaccination is an effective strategy to prevent severe COVID-19 cases in pediatric populations.
A new study published in eLife recommends taking Paxlovid three to five days after COVID-19 symptoms start to reduce viral loads and transmission. This optimal timing can help curb the spread of SARS-CoV-2 without population-wide restrictions.
Researchers at George Mason University's Biomedical Research Laboratory are conducting Plaque Reduction Neutralization Tests (PRNTs) on patient serum samples from Athari BioSciences. The study aims to analyze the neutralizing ability of antibodies against SARS-CoV-2.
Researchers at Baylor College of Medicine developed a new technology called tARC-seq to study SARS-CoV-2's genetic mechanism fueling its ability to generate variants. The study found that the mutation rate was higher than expected and identified hotspots in the virus's RNA where mutations occur more frequently.
A VACCELERATE Consortium survey study found that 57% of global infectious diseases experts ranked influenza as the top pandemic risk, with Disease X and SARS-CoV-2 also among the most concerning pathogens. The study highlights the need for continued preparedness and surveillance to prevent pandemics.
Researchers highlight the risk of novel SARS-CoV-2 variants emerging due to prolonged viral replication in immunocompromised individuals. Close genomic surveillance and early diagnostic tests are crucial to mitigate potential public health threats.
A new study found that nasal cells from children respond quickly to SARS-CoV-2 by increasing interferon, restricting viral replication. In contrast, nasal cells from elderly individuals produce more infectious virus particles and experience increased cell shedding and damage.
A study of 156 severe COVID-19 survivors found that nearly two-thirds experienced persistent impairments after one year, including physical, respiratory, psychiatric, and cognitive problems. The study highlights the life-altering impact of SARS-CoV-2 on these individuals, many of whom required long-term acute care hospitalization.
Researchers analyzed data on 9060 family physicians to find a correlation between those with the largest share of unvaccinated patients, typically serving marginalized communities, who had less support in their practices. These physicians were more likely to be male, older, and work in fee-for-service models than the remaining 90%.
A new lab-on-a-chip system combines optofluidics and nanopores to rapidly test for SARS-CoV-2 and Zika viruses with high accuracy. The tool, developed by UC Santa Cruz researchers, can detect viruses at extremely low concentrations and outperform PCR tests in some cases.
Scientists tested flood-control waterways near unsheltered encampments in Las Vegas, finding SARS-CoV-2 RNA in over 25% of samples. The study suggests a similar level of transmission among the unsheltered community as in the general population.
A study found that older adults have weaker T cell responses to COVID-19 mRNA vaccinations, resulting in poorer antibody responses and SARS-CoV-2 immune protection. The study suggests a relative deficiency in interferon-gamma-secreting CD4+ T cells may explain this response.
Georgia Tech researchers have developed a trivalent vaccine that offers broad protection against not only SARS-CoV-2 variants but also other bat sarbecoviruses. The groundbreaking vaccine has shown complete protection with no trace of virus in the lungs, marking a significant step toward a universal vaccine for coronaviruses.
A USC study reveals that SARS-CoV-2 causes a stage of mild symptoms followed by severe inflammation in some patients. The virus exploits two different pathways to interact with immune cells, one leading to inflammation and the other preventing it.
A study found that an annual vaccination campaign with a second dose for children under 2 years old and individuals aged 50 and over can significantly reduce hospitalizations, deaths, and healthcare spending. The optimal timing for the second vaccination is delivering it 5 months after initial vaccination.
A new study found that a viral infection can cause cognitive impairments by damaging the blood-brain barrier, leading to memory loss and learning difficulties. Researchers developed a gene therapy that stimulated the Wnt/beta-catenin pathway to prevent this damage and improve cognitive function in mice infected with SARS-CoV-2.
A new study published in Risk Analysis found that COVID-19's origin is unlikely to be natural, using a modified risk assessment tool. The researchers suggest an unnatural origin, potentially from a laboratory, cannot be easily dismissed.
Researchers found that initial vaccinations against the ancestral SARS-CoV-2 strain shape immune responses to newer variants BA.5 and XBB, with higher B cell repertoire leading to more effective cross-reactive immunity. This 'immunological imprinting' effect could impact future vaccine designs.
A novel bioengineered protein has been designed to bind to the spike proteins of SARS-CoV-2, with a hydrophobic pore enabling it to capture small molecules like Ritonavir. The study marks a significant advancement in COVID-19 treatment, showcasing a promising strategy for direct virus targeting.
An experimental study on over 6,000 unvaccinated individuals in Europe reveals that people perceive less risk of contagion when wearing masks and meeting in open spaces. The study highlights the importance of improving behavioral aspects of health policies and public health literacy.
A new platform has been developed to identify and optimize peptides targeting the SARS-CoV-2 envelope protein, a potential drug target for treating COVID-19. The study uses synthetic peptides to inhibit the virus's entry into host cells.
A Stanford University research team has developed a potential new anti-coronavirus drug that binds more tightly and durably than current treatments like Paxlovid. The compound, ML2006a4, performed well in preclinical experiments against SARS-CoV-2 variants that have evolved resistance to Paxlovid.
Researchers developed a protein-based vaccine candidate called SpyCage that induces an immune response in rodent models, clearing COVID-19 infections more quickly than controls. The platform has the potential to prevent infection and transmission of respiratory viruses like SARS-CoV-2 by inducing a mucosal immune response.
Researchers found that T cells can reshape their memory and maintain diversity against COVID-19 variants in response to successive mRNA vaccinations. The study revealed a shift among clonotypes, with a change from early responders to main responders after the second shot, suggesting a new dominant population of effector-memory T cells.
Researchers from SWPS University studied 216 grocery shops in Poland and found that few customers increased the likelihood of shop assistants keeping change. Sellers were more likely to give correct change to shoppers of the same gender as themselves, while wearing a mask or visor had no impact on honesty.
Researchers at MIT have developed a new type of nanoparticle that can both deliver vaccines and act as an adjuvant to generate a strong immune response. The particles, called metal-organic frameworks (MOFs), were shown to be effective in delivering the SARS-CoV-2 spike protein and boosting the immune system's response.
A recent study published in Lancet Infectious Diseases found that vaccinated individuals had a lower risk of severe COVID-19 outcomes compared to unvaccinated individuals. The study also showed significant reductions in hospitalization and death rates from COVID-19, particularly among older individuals and those with compromised immune...
Researchers at the University of Alberta have discovered a new class of antiviral drugs that stimulate interferon production to reverse the effect of SARS-CoV-2 on cells. The study shows that these drugs can significantly reduce the amount of virus found in the lungs and prevent severe symptoms.
A large binational study found that SARS-CoV-2 infection was associated with an increased risk of autoimmune inflammatory rheumatic diseases (AIRDs) extending up to 12 months after infection. Vaccination showed some protection against AIRDs, particularly among those who were vaccinated.
Researchers found a direct link between loss of smell and decreased olfactory neuron population in nasal mucosa. Early corticosteroid treatment improved recovery of olfactory abilities in animals.
A UC Riverside-led study has devised a way to make large quantities of the Membrane protein, which plays a crucial role in how SARS-CoV-2 acquires its spherical structure. The researchers found that when the M protein interacts with the membrane, it coaxes the membrane to curve, leading to the virus's characteristic shape.
Researchers found that e-liquids containing propylene glycol and vegetable glycerin enhance COVID-19 infection, while those with benzoic acid prevent it. Vapers are advised to quit or switch to e-liquids with acidic pH for better protection.
A long-term analysis of over 8,000 samples revealed that SARS-CoV-2 infection and vaccine-induced antibody responses are long-lasting. Booster vaccination equalized differences in antibody concentration between participants with and without pre-existing immunity.
A recent study published in JAMA Network Open found that vaccinated adults with hematologic cancers were at high risk of severe COVID-19, even after receiving treatment. The study included 6,122 patients and showed no significant decline in severe cases through mid-2022.
Research identifies interferon gamma (IFN-γ) as a potential biomarker for Long COVID fatigue and highlights an immunological mechanism underlying the disease. High levels of IFN-γ persisted in some patients for up to 31 months, coinciding with symptom resolution after vaccination.
A clinical study published in Microbiology Spectrum found that COVID-19 vaccines still provide a robust immune response in immunocompromised individuals, including cancer patients undergoing treatment. This finding is crucial for clinicians and patients, as it suggests vaccination can help prevent infection and disease progression.
A recent study published in the Journal of Clinical Medicine identifies potential biomarkers for ME/CFS diagnosis and treatment. Researchers found that patients can be divided into subgroups based on immune system function, revealing differences in intestinal barrier function and immune competence.
A study of 61,000 adults aged 45 or older found that those who adhered to physical activity guidelines before the pandemic had lower odds of developing or being hospitalized for COVID-19. This suggests that higher prepandemic physical activity levels may be linked to reduced risk of SARS-CoV-2 infection and hospitalization.
Researchers document various reasons for long-term clinical symptoms in patients infected with SARS-CoV-2. Key findings include immune system alterations, chronic inflammation, endothelial dysfunction, and mitochondrial issues contributing to post-COVID syndrome.
Researchers created a DNA-based vaccine that mimics the structure of a virus, inducing a strong antibody response against SARS-CoV-2. The vaccine uses a DNA scaffold carrying viral proteins, allowing the immune system to focus on the target antigen.
A Bayesian model analysis reveals how key covariates affect SARS-CoV-2 viral kinetics at individual and population levels. The study identifies intrinsic differences between Omicron and Delta variants, shedding light on their growth drivers.
A recent study published in Lancet Microbe suggests that immunocompromised patients are at higher risk for COVID infections, but prolonged infections lasting weeks to months are uncommon. The study found that specific conditions, such as B-cell cancers and autoimmune diseases, increase the risk of prolonged infections.
La Jolla Institute researchers discovered that prior exposure to a common cold coronavirus partially protects mice from lung damage during a subsequent SARS-CoV-2 infection. Harnessing 'cross-reactive' T cells may lead to novel vaccines with broad, pan-coronavirus protection.
A research team at the University of Göttingen has discovered 'protective switches' in the SARS-CoV-2 virus that shield it from attacks by the immune system. These molecular structures were found to stabilize the protein's structure against oxidative damage, allowing the virus to replicate effectively.
A new study finds that infants born full-term to mothers infected with COVID-19 during pregnancy are three times more likely to develop respiratory distress compared to uninfected infants. Vaccination prior to infection was found to be protective, reducing the risk by half.
A new study from Tulane University found that perlecan LG3, a protein commonly found in blood vessels and the brain, forms a stable bond with the COVID spike protein, enhancing the virus's ability to bind with cells. This discovery may lead to new forms of treatment or prevention for COVID-19.
Researchers at Brookhaven National Laboratory successfully produced large quantities of human ACE2 receptor protein in mouse cells, allowing for the study of viral receptors and potentially developing new therapies. The method could also facilitate the production of other complex proteins that have proven difficult to produce.
Research reveals memory T cells formed after Omicron breakthrough infection provide enhanced immunity against future variants. The study suggests the immune system adapts to combat emerging strains, leading to higher chances of inducing memory T cell defenses.
Researchers used the 2022 FIFA World Cup to study COVID-19 spread and hospitalizations at mass gatherings. They found that pre-travel screenings did little to prevent infections, but pre-match testing with rapid antigen or reverse transcription polymerase chain reaction tests was more effective.
Researchers found that the complement system remains activated in Long Covid patients, causing cell damage and tissue destruction. This abnormal activity can lead to thromboinflammation and other symptoms of the condition.
A new vaccine design has been developed by a UC Riverside-led research team, which uses preexisting immunity to the influenza virus to help kickstart the production of antibodies against SARS-CoV-2. The vaccine aims to speed up the immune response and provide better protection for people who still lack immunity to the coronavirus.